Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Dexamethasone 49Metformin 47Cyclophosphamide 42Saline Solution 38Cytarabine 34Sodium Chloride 32Bupivacaine 31Vincristine 27Cisplatin 26Propofol 25Methotrexate 25Letrozole 24Fluorouracil 24Dexmedetomidine 24Doxorubicin 23Fentanyl 22Carboplatin 22Etoposide 19Rituximab 18Morphine 18Bevacizumab 18Acetaminophen 18Lidocaine 17Granulocyte Colony-Stimulating Factor 17Prednisone 16Mercaptopurine 16Docetaxel 16Clomiphene 16Sevoflurane 15Ropivacaine 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × OTHER × Ranitidine × Clear all
NCT03145012 2023-02-08

Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity

Nova Scotia Health Authority

Phase 4 Completed
30 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡